Vertex Pharmaceuticals
(NASDAQ) VRTX
Vertex Pharmaceuticals Financials at a Glance
Market Cap
$132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$12.26B
Net Income (TTM)
$4.34B
EPS (TTM)
$16.87
P/E Ratio
30.96
Dividend
$0.00
Beta (Volatility)
0.57 (Low)
Dividend
$0.00
Beta (Volatility)
0.57 (Low)
Price
$498.59
Volume
131,553
Open
$524.02
Price
$498.59
Volume
131,553
Open
$524.02
Previous Close
$498.59
Daily Range
$498.28 - $525.00
52-Week Range
$362.50 - $533.67
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
0.57 (Low)
Price
$498.59
Volume
131,553
Open
$524.02
Previous Close
$498.59
Daily Range
$498.28 - $525.00
52-Week Range
$362.50 - $533.67
Estimated Earnings Date
Aug 3, 2026
VRTX News
VRTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Vertex Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
6,400
CEO
Reshma Kewalramani, MD
Website
www.vrtx.comHeadquarters
Boston, MA 02210, US
VRTX Financials
Key Financial Metrics (TTM)
Gross Margin
86.28%
Operating Margin
38.97%
Net Income Margin
35.40%
Return on Equity
23.93%
Return on Capital
21.11%
Return on Assets
16.38%
Earnings Yield
3.23%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
253.81M
Volume
131.55K
Avg. Volume
1.45M
Financials (TTM)
Gross Profit
$10.57B
Operating Income
$4.78B
EBITDA
$5.39B
Operating Cash Flow
$4.24B
Capital Expenditure
-$530.30M
Free Cash Flow
$3.71B
Cash & ST Invst.
$7.25B
Total Debt
$1.99B
Vertex Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.99B
+7.8%
Gross Profit
$2.59B
+7.8%
Gross Margin
86.85%
N/A
Market Cap
$132.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$21.73M
N/A
Employees
6,100
N/A
Net Income
$1.03B
+59.6%
EBITDA
$1.31B
+67.4%
Quarterly Fundamentals
Total Cash
$7.25B
+16.9%
Total Debt
$1.99B
+20.5%
Accounts Receivable
$2.00B
+10.6%
Inventory
$1.77B
+29.9%
Long Term Debt
$1.99B
+20.5%
Short Term Debt
$0.00
N/A
Return on Assets
16.38%
N/A
Return on Invested Capital
21.13%
N/A
Free Cash Flow
$1.29B
+66.4%
Operating Cash Flow
$1.43B
+74.4%